Caribou Biosciences (CRBU) stock soared 40% premarket after reporting positive early-stage trial results for its CAR-T therapies CB-011 and Vispa-cel. CB-011 showed strong efficacy and a manageable safety profile in multiple myeloma, while Vispa-cel demonstrated durable responses in B-cell non-Hodgkin lymphoma. The company plans to begin dose expansion by year-end.